CD59 and neuromyelitis optica: Additional potential advantages of upregulation of CD55 vs. CD59 for NMO therapy include the greater-fold increase in CD55 expression possible because of its low baseline expression compared to CD59 and inhibition of a different step in the complement pathway and hence possible synergy with CD59.